Cargando…

Effect of Extended-Release Niacin/Laropiprant Combination on Plasma Adiponectin and Insulin Resistance in Chinese Patients with Dyslipidaemia

Objectives. This study examined whether the increase of adiponectin associated with extended-release (ER) niacin/laropiprant combination attenuates the adverse effect of niacin on glucose and insulin resistance in Hong Kong Chinese patients with dyslipidaemia. Methods. Patients (N = 121) were treate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Miao, Yang, Ya-Ling, Masuda, Daisaku, Yamashita, Shizuya, Tomlinson, Brian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429190/ https://www.ncbi.nlm.nih.gov/pubmed/26063948 http://dx.doi.org/10.1155/2015/154014

Ejemplares similares

Extended Release Niacin-Laropiprant in Patients with Hypercholesterolemia or Mixed Dyslipidemias Improves Clinical Parameters
por: Vosper, Helen
Publicado: (2011)

Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia
por: Viljoen, Adie, et al.
Publicado: (2010)

Critical appraisal of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia
por: Hussein, Ayman A, et al.
Publicado: (2010)

Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia
por: Parhofer, Klaus G
Publicado: (2009)

Effects of Phenotypic and Genotypic Factors on the Lipid Responses to Niacin in Chinese Patients With Dyslipidemia
por: Hu, Miao, et al.
Publicado: (2015)

Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control
por: Bays, Harold E, et al.
Publicado: (2015)

Cost-effectiveness of extended-release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany
por: Michailov, Galin V., et al.
Publicado: (2011)

Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia
por: Farnier, Michel, et al.
Publicado: (2014)

Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes
por: Brinton, Eliot A., et al.
Publicado: (2016)

Hypophosphatemic effect of niacin extended release in ischemic kidney disease
por: Yasmeen, Ghazala, et al.
Publicado: (2015)

Enhanced Intestinal Absorption of Cholesterol along with Increased Chylomicron Remnants for De novo Progression of Coronary Stenosis
por: Masuda, Daisaku, et al.
Publicado: (2017)

Postprandial Hyperlipidemia and Remnant Lipoproteins
por: Masuda, Daisaku, et al.
Publicado: (2017)

Postprandial Glucose and Triglyceride Increases Along with the Endothelial Malfunction were Attenuated by the Administration of SGLT2 Inhibitor, Empagliflozin
por: Masuda, Daisaku, et al.
Publicado: (2020)

Serum HDL-Cholesterol Level Does Not Influence Cardiovascular Event Rate under Sufficient Lowering of LDL-Cholesterol by Pitavatatin in Patients with Stable Coronary Artery Disease
por: Masuda, Daisaku, et al.
Publicado: (2022)

Targeting mulitple dyslipidemias with fixed combinations – focus on extended release niacin and simvastatin
por: Pandian, Anbu, et al.
Publicado: (2008)

Biorelevant In Vitro Release Testing and In Vivo Study of Extended-Release Niacin Hydrophilic Matrix Tablets
por: Milanowski, Bartłomiej, et al.
Publicado: (2020)

Add-on-Statin Extended Release Nicotinic Acid/Laropiprant but Not the Switch to High-Dose Rosuvastatin Lowers Blood Pressure: An Open-Label Randomized Study
por: Kei, Anastazia, et al.
Publicado: (2011)

The Absence of Adiponectin Alters Niacin’s Effects on Adipose Tissue Inflammation in Mice
por: Graff, Emily C., et al.
Publicado: (2020)

Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases
por: Yamashita, Shizuya, et al.
Publicado: (2019)

Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases
por: Yamashita, Shizuya, et al.
Publicado: (2020)

New Horizons for Probucol, an Old, Mysterious Drug
por: Yamashita, Shizuya, et al.
Publicado: (2021)

Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin
por: Robinson, Jennifer G
Publicado: (2009)

Niacin Extended Release (ER)/Simvastatin (Simcor®): A Guide to its Use in Lipid Regulation
por: Lyseng-Williamson, Katherine A.
Publicado: (2012)

Changes in Lipoprotein Particle Number With Ezetimibe/Simvastatin Coadministered With Extended‐Release Niacin in Hyperlipidemic Patients
por: Le, Ngoc‐Anh, et al.
Publicado: (2013)

Quantification of Niacin and Its Metabolite Nicotinuric Acid in Human Plasma by LC-MS/MS: Application to a Clinical Trial of a Fixed Dose Combination Tablet of Niacin Extended-Release/Simvastatin (500 mg/10 mg) in Healthy Chinese Volunteers
por: Zhang, Pingping, et al.
Publicado: (2015)

Efficacy of Laropiprant in Minimizing Brain Injury Following Experimental Intracerebral Hemorrhage
por: Ahmad, Abdullah Shafique, et al.
Publicado: (2017)

Cultural Barriers in the Treatment of Dyslipidemia: A Survey of Japanese Physician Attitudes
por: Yamashita, Shizuya, et al.
Publicado: (2019)

Marked effects of novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate in severe hypertriglyceridemia: preliminary report
por: Iitake, Chie, et al.
Publicado: (2020)

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment
por: Haynes, Richard, et al.
Publicado: (2013)

Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis †
por: Yamashita, Shizuya, et al.
Publicado: (2023)

Laropiprant Attenuates EP3 and TP Prostanoid Receptor-Mediated Thrombus Formation
por: Philipose, Sonia, et al.
Publicado: (2012)

Laropiprant attenuates EP(3) and TP prostanoid receptor-mediated thrombus formation
por: Philipose, Sonia, et al.
Publicado: (2012)

Short term fat feeding rapidly increases plasma insulin but does not result in dyslipidaemia
por: Barzel, Benjamin, et al.
Publicado: (2014)

The Effects of Extended Release Niacin in Combination with Omega 3 Fatty Acid Supplements in the Treatment of Elevated Lipoprotein (a)
por: Helmbold, Alan F., et al.
Publicado: (2010)

Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy
por: Insull, William, et al.
Publicado: (2010)

Effect of extended-release niacin on hormone-sensitive lipase and lipoprotein lipase in patients with HIV-associated lipodystrophy syndrome
por: Chow, Dominic C, et al.
Publicado: (2008)

Niacin Increases Adiponectin and Decreases Adipose Tissue Inflammation in High Fat Diet-Fed Mice
por: Wanders, Desiree, et al.
Publicado: (2013)

Dietary Niacin Requirement of Juvenile Chinese Mitten Crab, Eriocheir sinensis
por: Liu, Xuran, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Simvastatin and Lovastatin/Extended-Release Niacin to Achieve LDL and HDL Goal Using NHANES Data
por: Armstrong, Edward P., et al.
Publicado: (2004)

Niacin in Maize
por: Burkholder, Paul R., et al.
Publicado: (1944)

Cannot write session to /tmp/vufind_sessions/sess_2tq8p7f49s1cqb4vs6ko7391qv